Bharat Biotech plans to invest Rs 3,000-4,000 crore in post-Covid shift

Not thinking about an IPO as of now, says chairman

Bharat Biotech is charting out its next leg of growth, for which it is investing Rs 3,000-4,000 crore in building vaccines, doing clinical trials, and having a manufacturing facility and partnerships.
 

At the same time, Krishna Ella-promoted Biovet is eyeing pole position as a veterinary vaccine player globally. Besides this, Anamay Biotech, led by Krishna Ella’s daughter Jalachari Ella, is focusing on the therapeutics segment, especially wound-care therapies.

“We invested Rs 600-700 crore during the pandemic for the development of Covaxinand other vaccines, and we have recovered more than that,” said Krishna Ella, executive chairman of Bharat Biotech. Business Standard